top of page
Search Results

659 items found for "Zhou Y"

Programs (5)

  • GPCRs in Pharmacology

    Whether you are a healthcare professional, researcher, or student in the life sciences, this course will enhance your knowledge and critical thinking skills in the field of pharmacology.

  • Step 1

    Start off your program by giving some basic information about what participants can expect to learn.

  • Step 2

    Break down your content into manageable steps. Use videos, images, and text to explain your main points, and set clear expectations and goals. You can also include files and audio as additional resources.

View All

Posts (205)

  • Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling

    dynamics ( e.g FLAsH biosensor [11]), cAMP production (e.g CAMYEL assay [12]) , and ERK activity (e.g YEN The ONE-GO biosensors, designed in a single vector, incorporate a G protein tagged with a YFP acceptor Zhou, Y., et al., Multiple GPCR Functional Assays Based on Resonance Energy Transfer Sensors.  Namkung, Y., et al., Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using

  • GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions

    proteins (Gether 2000), with numerous intermediate sub-states in between (Vauquelin and Van Liefde 2005; Yao disruption of natural spatial and temporal signaling patterns regulated by physiological systems (Wold and Zhou intervention for metabolic diseases such as liver disease, obesity and diabetes (Secor et al. 2021; Wold and Zhou

  • Pharmacological targeting of cGAS/STING-YAP axis suppresses pathological angiogenesis and...

    October 2022 Pharmacological targeting of cGAS/STING-YAP axis suppresses pathological angiogenesis and Meanwhile, cGAS deletion upregulated profibrotic Yes-associated protein (YAP) signaling in endothelial , which was evidenced by the attenuation of organ fibrosis in mice specifically lacking endothelial YAP Pharmacological targeting of cGAS/STING-YAP signaling by both a small-molecule STING agonist, SR-717, Further, pharmacological targeting of cGAS/STING-YAP axis exhibits the potential to alleviate liver and

View All

Other Pages (449)

View All
bottom of page